Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618
Year: 2009
Type: article
Study design: Clinical Trial
Source: Investigational New Drugs
Authors: Susanne M. Arnold, James Moon, Stephen K. Williamson, James N. Atkins, Sai-Hong I. Ou, Michael LeBlanc, Susan G. Urba
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G117886320, G1202672505, G1216887118, SOUTHWEST ONCOLOGY GROUP, G1257575315, G1375689152, G1545560008, G1911575068, G1985252453, G2276667821, G2435896781, G2485941414, G2646278872, G2750730928, Ozark Health Ventures, LLC dba Cancer Research for the Ozarks, GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM, SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER, G313314762, G3242537740, Southeast Cancer Control Consortium, Inc, G3295642875, G3521018462, G36541222, G3710026009, G3737421695, G379387698, G425646771, G4292856267, Southwest Oncology Group, SOUTHWEST ONCOLOGY GROUP, G5264753430, G591690631, SOUTHWEST ONCOLOGY GROUP, SOUTHWEST ONCOLOGY GROUP, G7520596819, G8006406963, G8036334546, SOUTHWEST ONCOLOGY GROUP, G8740717309, G90079629, G933283670, G971274320
OpenAlex ID: W2019684848